Thu, Apr 18, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Industry Updates

UBS O'Connor expands with healthcare-focused investment team

Wednesday, February 23, 2022
Opalesque Industry Update - UBS O'Connor, the multi-strategy hedge fund manager within UBS Asset Management, announced today that it has hired Jason Bonadio MD, Robert Sweeney MD, and Adam Sandler MD to manage a relative value equity strategy focusing on the healthcare therapeutics industry.

"Our new investment team at O'Connor brings a combination of biomedical expertise and investment experience that enables us to identify healthcare companies trading well below their intrinsic value. This segment of the market, which has always been prone to high dispersion of returns and high barriers to investment participation, due to the scientific and data complexity of the industry, creates an investment opportunity set ideal for alpha generation and uncorrelated returns," said Kevin Russell, Chief Investment Officer of O'Connor.

Dr. Jason Bonadio joins as a Healthcare Portfolio Manager. Prior to this role, he co-founded Alera Partners, a long/short equity healthcare fund investing in the biotechnology, medical technology, pharmaceutical and life science tools sectors. Dr. Bonadio was also a founding partner and a co-portfolio manager of the FrontPoint Healthcare Funds.

Dr. Robert Sweeney joins as a Healthcare Research Analyst. Dr. Sweeney is a board-eligible surgeon that joined Alera Partners in 2021. Previously, he worked as a sell-side equity research analyst at H.C. Wainwright, with coverage across therapeutic areas and medical devices. He is currently a Ph.D. candidate in Immunology at the Icahn School of Medicine at Mount Sinai in NYC.

Dr. Adam Sandler joins as a Healthcare Research Analyst. Dr. Sandler is currently the chief resident in the Department of Occupational Medicine at Mount Sinai. He joined Alera Partners in 2021 and was previously a healthcare analyst at Guidepoint Global. After graduating, cum laude from Harvard University in 2004, he received awards for his work from the New York Academy of Medicine, Crohn's and Colitis Foundation of America, and Adenosine Therapeutics at Mount Sinai School of Medicine.

O'Connor has USD 11.2 billion in assets under management as of February 1, 2022. UBS Asset Management is a large scale asset manager with over USD 1.2 trillion in invested assets across its traditional asset management, hedge fund, real estate, infrastructure and private equity businesses.

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1